PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28108625-0	2017	Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-kappaB Activation.	balsalazide	26-37	nuclear factor kappa B subunit 1	Homo sapiens	91-100	
28108625-4	2017	The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets.	balsalazide	48-59	nuclear factor kappa B subunit 1	Homo sapiens	135-144	
28108625-4	2017	The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets.	balsalazide	48-59	nuclear factor kappa B subunit 1	Homo sapiens	177-186	
28108625-4	2017	The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets.	balsalazide	48-59	nuclear factor kappa B subunit 1	Homo sapiens	177-186	
28108625-8	2017	These results demonstrate that parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-kappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.	balsalazide	72-83	nuclear factor kappa B subunit 1	Homo sapiens	118-127